Since then, accumulating evidence have linked overexpression of SET, aberrant SET splicing, and cellular localization to cancer progression and development of neurodegenerative tauopathies such as Alzheimer’s disease. This evidence concerns the gene SET and early-onset autosomal dominant Alzheimer disease.